Contact Information: Contact Name: Ali Al-Khattawi E-mail: ali@mesox.co.uk Website: https://mesox.co.uk/ Funding required: £750,000 (£200,000 already secured)
The Solution MESOX platform technology, MesoPAC, is a mesoporous carrier technology widely applicable for the delivery of challenging small/mid- sized molecules enhancing their bioavailability, amorphous form stability and controlling release. It overcomes the current approaches drawbacks (incomplete-release/low drug loading/instability) whilst offering new IP opportunities. MesoPAC uses a scalable GMP process and is proven in-vivo (doubling bioavailability). MesoPAC’s unique cellulosic microparticle polymer has a mesoporous structure (20nm) which, through a novel combination of the spatial confinement effect, surface anchoring, and strong hydrophobic interactions, entraps and confines loaded drug molecules in the amorphous form. At bench-scale, this carrier is proven to offer: • 32% higher dissolution of Felodipine versus mesoporous silica Syloid(r)XDP-3050 (96.8±8%-wt. versus 65±4%-wt. i.e. incomplete release within 2-hours). • Stabilising effect to the amorphous form preventing recrystallisation proven through • Stabilising further enhanced by our spray- drying loading method, proven to reduce carrier’s pore volume by ~47% to achieve high loading efficiency (\>90% drug recovery) - other methods reduce pore volume by 10- 20% using e.g. solvent impregnation/rotary evaporation. • Typically, 30%-w/w drug loading is achieved, in- line with other pioneering carrier technologies accelerated/long-term stability studies. Removes the need for precipitation/ crystallisation inhibitors.
MESOX develops innovative drug delivery technologies based on mesoporous carriers to improve the bioavailability and efficacy of pharmaceuticals. Our solutions aim to reduce the unnecessary dose exposure/frequency and improve patient compliance, ultimately leading to better patient outcomes. We work with pharmaceutical and biotechnology companies to bring challenging therapeutics to market. The Problem Around 9 out of 10 molecules in the pipeline have low bioavailability leading to products with higher than necessary doses and associated side-effects or poor exposure/efficacy if the problem is ignored. Discovery efforts are driving more molecules beyond-the-rule-of-5-(Bro-5) space with no viable formulation solution further complicating their successful translation to market.
Made with FlippingBook Learn more on our blog